Ortho Clinical Diagnostics
VITROS® COVID-19 TESTING SOLUTIONS
Introducing Ortho's VITROS® SARS-CoV-2 Antigen Test
Ortho is expanding access to testing with the addition of a high-throughput, highly accurate test for acute detection of the SARS-CoV-2 virus.
One system for your COVID-19 infection and antibody testing needs.
Meeting the demands of the pandemic with reliable, high-throughput testing solutions for both SARS-CoV-2 infection and antibody detection. Ortho’s integrated VITROS® system allows labs to concurrently run routine and COVID-19 tests, confidently delivering trusted results.
The VITROS® SARS-CoV-2 Antigen Test
Ortho’s Antigen Test is a high-throughput, highly accurate test that detects acute infection of SARS-CoV-2.
Learn More >The VITROS® COVID-19 Total and IgG Antibody Test
Ortho’s Antibody Test detects antibodies to the S1 protein, a primary target for neutralizing antibodies against SARS-CoV-2.
THE ORTHO DIFFERENCE
The reliable testing solution you and your community can count on.
Ortho is among the first to offer both SARS-CoV-2 infection and antibody testing on the same high-throughput in-vitro diagnostics system.
Ortho has three VITROS® COVID-19 Testing Solutions that can be run on the same high-throughput system: VITROS® COVID-19 Total, VITROS® COVID-19 IgG and VITROS® COVID-19 Antigen Test.
Ortho's proprietary VITROS® Technology enables dynamic lab operation.
The waterless and fully automated VITROS® system prepares your lab for maximum flexibility to respond to the needs of the pandemic.
Enabling technologies
Disposable tips, microsensor quality control, and Intellicheck Error-Reducing technology all work together to ensure you always get the most reliable results, every single time.
Easily reconfigure your lab
VITROS® doesn’t require plumbing, which means you can adapt and enhance your lab’s workflow to the changing needs of the pandemic.
Less maintenance
Ready when you need it with 24-hour ready mode and long calibration intervals at 28 days.
Content for New div Tag Goes Here
Industry-leading service and support
Ortho Care™ holistic support program is #1 in service, virtual training, with a 98% uptime guarantee*.
Content for New div Tag Goes Here*Ortho Care™ is Ortho’s global award-winning service and support program that allows you to focus on patient care, not analyzer care. Ortho Care™ holistic support program is #1 in service, virtual training, with a 98% uptime guarantee*. Training: Gain access to unlimited Virtual Key Operator, General Operator and Continuing Education Training – enabling you to leverage Ortho’s solutions wherever you are.
Ortho’s VITROS® COVID-19 Solutions are more than just an asset to your lab. They’re an asset to your community.
Our COVID-19 Solutions will:
Improve lab efficiency
High throughputs, short turnaround times, up-to-date data, and easy-to-use automated systems will help improve the efficiency of your lab during this tumultuous time.
Provide expertise
The latest COVID-19 data and insights, fast, reliable results, and our VITROS® system’s unique technology will help position your hospital as a leader in your community during this pandemic.
Help stop the spread
Fast, reliable COVID-19 testing for both virus and antibody detection can help community leaders make informed decisions about public health.
Content for New div Tag Goes HereBecause Every Test is a Life
Our VITROS® COVID-19 Solutions are just our newest way to help you overcome today’s challenges and provide better care for your patients and your community. But all of Ortho’s solutions, from COVID-19 and beyond, are designed with you and your patient in mind. Because every test is a life.
More information
This website contains information that is targeted to a wide range of audiences and could contain product details or information otherwise not valid or applicable to your country. Please remember to consult your local legal restrictions, regulations, registrations or intended uses in the country of your origin. Product availability may vary from country to country and is subject to varying regulatory requirements.
The VITROS Anti-SARS-CoV-2 Total and IgG Antibody tests and the VITROS SARS-CoV-2 Antigen Test have not been FDA cleared or approved. They have been authorized by the FDA under an Emergency Use Authorization and testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform moderate or high complexity tests. The VITROS Antibody tests have been authorized only for the detection of either Total or IgG antibodies from SARS-CoV-2, not for any other viruses or pathogens, and results should not be used as the sole basis for diagnosis. The VITROS Antigen test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. These tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Why subscribe to Premium content?
Enjoy unlimited access to the very best insights across the diagnostic community including industry reports and regular webinars from thought leaders.
- Trusted opinion
- Tailored to you
- It’s FREE
Sign up for Free!
- Access to Premium resources
- Premium Rewards including offers, competitions and events exclusives
- Premium subscriber-only newsletters and briefings